Suppr超能文献

妊娠期 COVID-19 疫苗的安全性:系统评价和荟萃分析。

Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.

机构信息

Centro de Investigación de Epidemiología y Salud Pública (CIESP) - Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Argentina.

The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

出版信息

Vaccine. 2023 Jun 7;41(25):3688-3700. doi: 10.1016/j.vaccine.2023.03.038. Epub 2023 Mar 27.

Abstract

BACKGROUND

Assessment of COVID-19 vaccines safety during pregnancy is urgently needed.

METHODS

We conducted a systematic review and meta-analysis to evaluate the safety of COVID-19 vaccines, including their components and technological platforms used in other vaccines during pregnancy and animal studies to complement direct evidence. We searched literature databases from its inception to September 2021 without language restriction, COVID-19 vaccine websites, and reference lists of other systematic reviews and the included studies. Pairs of reviewers independently selected, data extracted, and assessed the risk of bias of the studies. Discrepancies were resolved by consensus. (PROSPERO CRD42021234185).

RESULTS

We retrieved 8,837 records from the literature search; 71 studies were included, involving 17,719,495 pregnant persons and 389 pregnant animals. Most studies (94%) were conducted in high-income countries, were cohort studies (51%), and 15% were classified as high risk of bias. We identified nine COVID-19 vaccine studies, seven involving 309,164 pregnant persons, mostly exposed to mRNA vaccines. Among non-COVID-19 vaccines, the most frequent exposures were AS03 and aluminum-based adjuvants. A meta-analysis of studies that adjusted for potential confounders showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Neither the reported rates of adverse pregnancy outcomes nor reactogenicity exceeded expected background rates, which was the case for ASO3- or aluminum-adjuvanted non-COVID-19 vaccines in the proportion meta-analyses of uncontrolled studies/arms. The only exception was postpartum hemorrhage after COVID-19 vaccination (10.40%; 95% CI: 6.49-15.10%), reported by two studies; however, the comparison with non-exposed pregnant persons, available for one study, found non-statistically significant differences (adjusted OR 1.09; 95% CI 0.56-2.12). Animal studies showed consistent results with studies in pregnant persons.

CONCLUSION

We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Additional experimental and real-world evidence could enhance vaccination coverage. Robust safety data for non-mRNA-based COVID-19 vaccines are still needed.

摘要

背景

迫切需要评估 COVID-19 疫苗在妊娠期间的安全性。

方法

我们进行了系统评价和荟萃分析,以评估 COVID-19 疫苗(包括其成分和其他疫苗中使用的技术平台)在妊娠期间和动物研究中的安全性,以补充直接证据。我们从数据库建立之初到 2021 年 9 月,无语言限制地搜索了文献数据库、COVID-19 疫苗网站以及其他系统评价和纳入研究的参考文献列表。由两名审查员独立选择、提取数据并评估研究的偏倚风险。通过共识解决分歧。(PROSPERO CRD42021234185)。

结果

我们从文献检索中检索到 8837 条记录;纳入 71 项研究,共涉及 17719495 名孕妇和 389 只妊娠动物。大多数研究(94%)在高收入国家进行,为队列研究(51%),15%被归类为高偏倚风险。我们确定了 9 项 COVID-19 疫苗研究,其中 7 项涉及 309164 名孕妇,主要暴露于 mRNA 疫苗。在非 COVID-19 疫苗中,最常见的暴露是 AS03 和铝基佐剂。调整潜在混杂因素的研究的荟萃分析显示,无论疫苗或接种疫苗的妊娠阶段如何,与不良结局均无关联。不良妊娠结局的报告发生率或反应原性均未超过预期背景发生率,这在非对照研究/臂的 ASO3 或铝佐剂非 COVID-19 疫苗比例荟萃分析中也是如此。唯一的例外是 COVID-19 疫苗接种后的产后出血(10.40%;95%CI:6.49-15.10%),由两项研究报告;然而,与一项研究中可用的未暴露孕妇相比,差异无统计学意义(调整后的 OR 1.09;95%CI 0.56-2.12)。动物研究结果与孕妇研究一致。

结论

我们未发现目前接种的 COVID-19 疫苗在妊娠期间存在安全性问题。额外的实验和真实世界证据可以提高疫苗接种率。仍需要非基于 mRNA 的 COVID-19 疫苗的稳健安全性数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ef9/10311988/e87ed71030ff/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验